OBJECTIVES: The number of patients suffering cardiovascular diseases increase annually worldwide. The main objective of this study was to evaluate the utilisation of renin- angiotensin system agents (C09), as the group of medicines with highest consumption in terms of expenditures units, number of packages and DDD in Slovak Republic within the years 2006 -2010. METHODS: Analysed data were abstracted from two databases – PharmaData and IMS. Data were studied in accordance with Daily Defined Dosage (DDD), financial units (€) and number of packages prescribed every year. RESULTS: The consumption of Renin –Angiotensin system agents increased within the years 2006-2010 as in number of packages as well as in terms of financial units and DDD. The most prescribed were plain ACE Inhibitors (C09A) and they raised in number of packages from 3,528,618 (2006) to 483,4360 (2008), and slightly decreased until 2010 (4,409,095). In accordance with financial expenditures, the highest consumption was in the group Angiotensin II receptor blockers  plain (C09C). The expenses increased sharply from 58,4540€ in 2006 to 1,397,097€ in 2010. The financial expenses on Angiotensin II receptor blockers combined (C09D) raised from 440,299€ (2006) to 107,2043€ (2010). According to DDD the highest consumption can be seen in C09A – ACEI plain, followed by C09B – ACEI combined, C09C Angiotensin II receptor blockers plain and the lowest in group C09D Angiotensin II receptor blockers combined. CONCLUSIONS: This study concluded that ACEI plays an important role in treatment of cardiovascular diseases, they are preferred, most prescribed and not so expensive as Angiotensin II receptor blockers.